Biochemical markers of bone turnover: Preanalytical variability and recommendations for use;Les marqueurs biologiques du remodelage osseux: Variations pre-analytiques et recommandations pour leur utilisation

Annales de Biologie Clinique

Volumn 58, Issue 6, 2000, Pages 683-704

  Garnero, P ^a   Bianchi, F ^a   Carlier, M C ^a   Genty, V ^a   Jacob, N ^a   Kamel, S ^a   Kindermans, C ^a   Plouvier, E ^a   Pressac, M ^a   Souberbielle, J C ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bone markers; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; CALCIUM; COLLAGEN; HYDROXYPROLINE; ORAL CONTRACEPTIVE AGENT; OSTEOCALCIN;

ADOLESCENCE; ADULT; AGE; BONE; BONE DISEASE; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CHILD; CLINICAL PRACTICE; COMPARATIVE STUDY; EXERCISE; FEMALE; GENDER; HUMAN; IMMOBILIZATION; LABORATORY DIAGNOSIS; LACTATION; LONGITUDINAL STUDY; MALE; MEDICAL SOCIETY; MENSTRUAL CYCLE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PREGNANCY; REVIEW; SEASON; SEASONAL VARIATION; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DISEASES; BONE REMODELING; BONE RESORPTION; CALCIUM; CHILD; COLLAGEN; CONTRACEPTIVES, ORAL; EXERCISE; FEMALE; HUMANS; HYDROXYPROLINE; IMMOBILIZATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PREGNANCY; SEASONS; SEX FACTORS; SPECIMEN HANDLING;

EID: 0033674657     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (164)

1. Perspectives in alkaline phosphatase research
2. Enzymes in mineralizing systems: State of the art
3. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease
4. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase in serum
5. Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone
6. Presence of messenger ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripheral blood platelets
7. Increased bone formation in osteocalcin-deficient mice
8. Measurement of serum osteocalcin with a human specific two site immunoradiometric assay
9. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro
10. Amino and carboxyl propeptides in bone collagen fibrils during embryogenesis
11. Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology
12. Products of bone collagen metabolism
13. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases
14. Immunoassay for intact amino-terminal propeptide of human type I procollagen
15. Amino terminal propeptide of type I collagen (PINP) is a more sensitive marker of bone turnover than C-terminal propeptide in osteoporosis
16. A simplified procedure for the measurement of total hydroxyproline in urine
17. Determination of hydroxyproline by high pressure liquid chromatography
18. The biosynthesis of collagen and its disorders (first of two parts)
19. The biosynthesis of collagen and its disorders (second of two parts)
20. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation
21. Factors affecting the assay of urinary 3-hydroxypyridinium crosslinks of collagen as markers of bone resorption
22. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis
23. Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared
24. Development of an immunoassay for urinary galactosylhydroxylysine
25. Osteoclastic tartrate-resistant acid phosphatase (Acp 5): Its localization to dendritic cells and diverse murine tissues
26. Serum osteocalcin, bone alkaline phosphatase isoenzyme and plasma tartrate resistant acid phosphatase in patients on chronic maintenance hemodialysis
27. Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase
28. Immunoassay of a tartrate-resistant acid phosphatase in serum
29. Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay
30. Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies
31. Cross-linking in collagen and elastin
32. Analysis of pyridinoline, a cross-linking compound of collagen fibers in human urine
33. Multiple molecular forms of pyridinolines crosslinks excreted in human urines evaluated by chromatographic (HPLC) and immunoassay (Elisa) methods
34. Quantitation of hydroxypyridinium cross links in collagen by high performance liquid chromatography
35. Quantitative analysis of pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high performance chromatography
36. Immunoassay for urinary pyridinoline: The new marker of bone resorption
37. Direct enzyme linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption
38. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine
39. Collagen crosslinks in metabolic bone disease
40. Radioimmunoassay for the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen: A new serum marker of bone collagen degradation
41. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: The effect of nandrolone decanoate and hormone replacement therapy
42. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate
43. Correlation between bone metabolic markers and bone scan in prostatic cancer
44. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate cancer
45. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: Loss of antigenicity by treatment with cathepsin K
46. Determination of bone markers in pycnodysostosis: Effects of cathepsin K deficiency on bone matrix degradation
47. Immunoassay for quantifying type I collagen degradation products in urine evaluated
48. Characterization of urinary degradation products derived from type I collagen
49. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: A biological clock of protein aging with clinical potential
50. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha I chain in Paget's disease of bone
51. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease
52. Evidence that serum NTX (collagen I N-telopeptides) can act as an immunochemical marker of bone resorption
53. Serum crosslaps one step Elisa: First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen
54. Matrix sialoprotein of developing bone
55. Localization of bone sialoprotein (BSP) expression to sites of mineral tissue formation in fetal rat tissue by in situ hybridization
56. Characterization of porcine bone sialoprotein: Primary structure and cellular expression
57. Expression of bone sialoprotein (BSP) in developing human tissues
58. Platelets contribute to circulating levels of bone sialoprotein in humans
59. Further characterization of interaction between bone sialoprotein (BSP) and collagen
60. Increased release of bone sialoprorein into synovial fluid reflects tissue destruction in rheumatoid arthritis
61. Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay
62. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease
63. Novel markers of bone resorption and comparison with established urinary indices
64. Biochemical markers for assessing skeletal growth
65. Biochemical markers of bone turnover in girls during puberty
66. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
67. Relationship of bone turnover to bone density and fractures
68. Increase in serum bone gamma carboxyglutamic acid protein with aging in women
69. Age-related changes in bone turnover in men
70. Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: Age- and sex-related changes and reference limits
71. Serum osteocalcin and other indices of bone formation: An 8-decade population study in healthy men and women
72. Differences in serum bone gla protein with age and sex
73. A comparison of the urinary excretion of bone resorptive products in white and black children
74. Body composition and gonadal steroids in older white and black women
75. Racial differences in pre- and postmenopausal bone homeostasis: Association with bone density
76. An investigation of ethnic differences in bone mineral, hip axis length, calcium metabolism and bone turnover between West African and Caucasian adults living in the United Kingdom
77. Ethnic and gender differences in bone mineral density and bone turnover in young adults: Effect of bone size
78. Effects of ethnicity and age or menopause on the remodeling and turnover of lilac bone: Implications for mechanisms of bone loss
79. Increased serum levels of N-telopeptides (NTx) of bone collagen in postmenopausal Nigerian women
80. The effect of pregnancy on bone density and bone turnover
81. Bone metabolism after human parturition and the effect of lactation: Longitudinal analysis of serum bone-related proteins and bone mineral content of the lumbar spine
82. Bone mass and long-term monophasic oral contraceptive treatment in young women
83. Bone metabolism in young women taking a monophasic pill containing 20 mcg ethinylestradiol: A prospective study
84. Bone mass and long-term monophasic oral contraceptive treatment in young women
85. Oral contraception affects osteocalcin serum profiles in young women
86. Bone density in users of combined oral contraception: Preliminary reports of a pilot study
87. Plasma osteocalcin: Biological variations and reference limits
88. Decreased bone turnover in oral contraceptive users
89. Longitudinal study of bone loss in pre and perimenopausal women: Evidence for bone loss in perimenopausal women
90. Changes in bone mass and bone turnover following distal forearm fracture
91. Changes in bone mass and bone turnover following ankle fracture
92. Fracture induces long-term effects on bone turnover in humans
93. Bone mineral in pre- and postmenopausal women with insulin-dependent and non-insulin-dependent diabetes mellitus
94. Biochemical markers of bone turnover in patients with thyroid dysfunctions and in euthyroid controls: A cross-sectional study
95. Serum bone gla-protein increases with aging in normal women: Implications for the mechanism of age-related bone loss
96. Evaluation of the Hybritech Tandem-R-Ostase immunoradiometric assay for skeletal alkaline phosphatase
97. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis
98. Measurement of the cross linking compound, pyridinoline, in urine as an index of collagen degradation in joint disease
99. Urinary excretion of pyridinium crosslinks of collagen correlated with joint damage in arthritis
100. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis
101. L'osteoporose cortisonique de l'adulte
102. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen
103. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: Effects of sex, age, and metabolic bone disease
104. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs
105. Analysis of urinary pyridinoline and deoxypyridinoline in patients undergoing long-term anticonvulsant drug therapy
106. The effects of thiazide diuretics on calcium metabolism in the aged
107. Thiazides and seasonal bone change in healthy postmenopausal women
108. Effects of short-term, high dose, heparin therapy on biochemical markers of bone metabolism
109. Effects of short-term low-dose heparin administration on biochemical parameters of bone turnover
110. Impaired carboxylation of osteocalcin in warfarin-treated patients
111. The proportion of carboxylated to total or intact osteocalcin in serum discriminates warfarintreated patients from control subjects
112. Serum ionized calcium, intact PTH and novel markers of bone turnover in bedridden elderly patients
113. High bone turnover in the elderly
114. Lower mobility and markers of bone resorption in the elderly
115. Changes in markers of bone formation and resorption in a bed rest model of weightlessness
116. The effects of twelve Weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects
117. Modifications of bone and connective tissue after orthostatic bedrest
118. Collagen cross-link excretion during space flight and bed rest
119. Diurnal variations in serum markers of type I collagen synthesis and degradation in healthy premenopausal women
120. Comparison of analytical performance and biological variability of three bone resorption assays
121. Effects of the circadian variations in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women
122. Changes in the carboxy-terminal propeptide of type I procollagen and other markers of bone formation upon five days of bed rest
123. Diurnal variation of bone mineral turnover in elderly men and women
124. Weight gain reverses bone turnover and restores circadian variation of bone resorption in anorexic patients
125. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption
126. Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy
127. Diurnal rythm of cross-laps in human serum
128. Changes in bone resorption during the menstrual cycle
129. Possible variation in bone resorption during the normal menstrual cycle
130. Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women
131. Urinary biochemical markers for bone resorption during the menstrual cycle
132. Changes in biochemical markers of osteoblastic activity during the menstrual cycle
133. Seasonal variation of biochemical indexes of bone turnover: Results of a population-based study
134. Seasonal differences in biochemical parameters of bone remodelling
135. Seasonal variation of serum bone gla protein
136. Lack of seasonal variation in bone mass and biochemical estimates of bone turnover
137. Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. Epidos Study Group
138. Bone metabolic changes in Antarctic wintering team members
139. Exercise: Moving in the right direction
140. Bone formation and resorption biological markers in cosmonauts during and after a 180-day space flight (Euromir 95)
141. Differences in basal and postexercise osteocalcin levels in athletic and non athletic humans
142. Low bone mass and high bone turnover in male long distance runners
143. Effect of resistance exercise training on bone formation and resorption in young male subjects assessed by biomarkers of bone metabolism
144. Transient dissociation of bone metabolism induced by high performance exercise: A study in elite marathon runners
145. Evidence for increased bone formation following a brief endurance-type training intervention in adolescent males
146. Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males
147. Changes in bone turnover induced by aerobic and anaerobic exercise in young males
148. Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability
149. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates
150. Biochemical markers of bone turnover, endogeneous hormones and the risk of fractures in postmenopausal women: The Ofely study
151. Afternoon sampled serum crosslaps predicts hip fracture in the elderly women: The Epidos study
152. Measurements of deoxypyridinoline and hydroxyproline in 24 h, first morning and second morning urine samples
153. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy
154. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The Ofely Study
155. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen
156. Measurement of a more stable region of osteocalcin in serum by Elisa with two monoclonal antibodies
157. Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women
158. Standardization trial of biochemical markers of bone turnover
159. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine
160. Responses of several markers of bone collagen degradation to calcium supplementation in postmenopausal women with low calcium intake
161. High long term variability in biochemical markers of bone turnover
162. Long-term variability of biochemical markers of bone turnover in postmenopausal women
163. Monitoring alendronate therapy for osteoporosis
164. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy